XOMA Stock Rating Upgraded by StockNews.com

XOMA (NASDAQ:XOMA) has recently seen its stock rating upgraded by StockNews.com. The firm raised its rating from "sell" to "hold" in a report released on Friday.

In a separate development, HC Wainwright reaffirmed its "buy" rating for XOMA shares, assigning a price target of $104.00 in a report published on Wednesday.

XOMA Stock Performance

On Friday, XOMA shares experienced a slight decline, falling by $0.18 to settle at $20.88. Approximately 81,363 shares changed hands during the trading session, which is considerably higher than the average volume of 26,540 shares. Over the past year, XOMA has reached a low of $19.92 and a high of $35.00. The biotechnology company is valued at a market cap of $250.12 million, showing a PE ratio of -6.00 and a beta of 1.00. Currently, its 50-day moving average price is $24.37, while the 200-day moving average price stands at $27.14. Moreover, XOMA has a strong current ratio and quick ratio, both at 7.52, and a debt-to-equity ratio of 1.28.

XOMA Corporation last reported its quarterly earnings on March 17th, revealing earnings per share (EPS) of -$0.46 for the quarter. This result fell short of analysts' expectations, which had predicted an EPS of -$0.29, indicating a miss of $0.17. The company recorded a negative return on equity of 24.95% and a significantly negative net margin of 151.34%, with quarterly revenue reported at $8.70 million, slightly below the consensus estimate of $8.75 million. Looking forward, analysts predict that XOMA will end the current fiscal year with an EPS of -$1.41.

Insider Trading

In related news, a significant shareholder, Bvf Partners L.P./Il, sold a substantial amount of stock, offloading 500,742 shares on January 24th at an average price of $26.10 per share. This transaction amounted to a total of $13,069,366.20 and was reported to the SEC. Currently, company insiders hold about 7.20% of the stock.

Institutional Changes

Recently, institutional investors and hedge funds have adjusted their positions in XOMA. Geode Capital Management LLC increased its stake by 0.6% in the third quarter, now owning 182,741 shares valued at approximately $4.84 million. Barclays PLC significantly boosted its holdings by 300.7%, acquiring a total of 11,256 shares worth about $298,000. BNP Paribas Financial Markets also raised its stake in XOMA by 95.0%, securing 1,632 shares valued at $43,000. State Street Corp and New York State Common Retirement Fund have likewise expanded their stakes, owning 142,857 and 2,362 shares respectively. Notably, institutional investors collectively own 95.92% of the company’s stock.

About XOMA Corporation

XOMA Corporation operates as a biotech royalty aggregator, focusing on acquiring rights to future milestone and royalty payments tied to various therapeutic candidates both in the United States and the Asia Pacific region. The company targets early to mid-stage clinical assets which are typically licensed to partners, as well as acquiring revenue streams from late-stage clinical or commercial assets.

XOMA, Stocks, Rating